Ignite Creation Date:
2024-05-05 @ 12:10 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00267748
Status:
COMPLETED
Last Update Posted:
2011-09-05
First Post:
2005-12-20
Brief Title:
Sunitinib Malate Schedule 42 vs Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer RCC
Sponsor:
Pfizer
Organization:
Pfizer
Organization Data
Organization:
Pfizer
Class:
INDUSTRY
Study ID:
A6181065
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Pfizer
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
Director Clinical Trial Disclosure Group
Old Organization:
Pfizer Inc